期刊文献+

喜树碱类抗肿瘤药物作用模式的柔性分子对接研究 被引量:8

Flexible Molecular Docking Studies of Antineoplastic Camptothecin Derivatives on DNA-topoisomerase I Complex
下载PDF
导出
摘要 研究采用柔性分子对接技术 ,将 15个喜树碱类化合物对接到拓扑异构酶I (TopoI) DNA切割复合物中 ,从原子水平和分子力场角度阐明了喜树碱类抗肿瘤药物与DNA ,TopoI的相互作用机制 .研究发现 ,喜树碱分子插入TopoI DNA复合物的切割位点 ,并与Asn72 2 ,Asp5 3 3 ,Lys5 3 2和Lys72 0形成氢键作用网络 .定量构效关系研究进一步表明喜树碱分子可以与TopoI DNA切割复合物形成电荷迁移作用 .该对接模型系统解释了喜树碱类化合物的构效关系、定点突变等诸多实验事实 ,为下一步设计。 Based on the crystallographic structure of human topoisomerase I (Togo I)-DNA covalent complex, a general model for the ternary drug-DNA-Topo I complex for camptothecin (CPT) derivatives has been developed using flexible docking techniques and thus elucidated the mode of action of CPT compounds interacting with Topo I and DNA from the atomic level for further design of novel potent CPT derivatives. In our model, CPT intercalated between the - 1 and + 1 base pairs of the cleavage site, stabilized further by H-bonding network between Asn722, Asp533, Lys532, Lys720 of Topo I and itself. Quantitative structure-activity relationship (QSAR) studies of 20 A-ring substituted CPT derivatives indicate that there may exist pi-pi charge transfer interaction between CPT derivatives and Topo I-DNA complex. Our model of action for CPT provides an excellent fit between CPT and the binding site and is significantly consistent with the current knowledge of experimental mutations that render CPT resistant and structure-activity relationships of CPT derivatives, etc. This model provides a rational basis for further design and synthesis of novel potent CPT antitumor drugs.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2003年第11期1860-1866,共7页 Acta Chimica Sinica
基金 "973"国家重点基础研究项目子课题 (No.G1 9980 51 1 0 4 ) 国家自然科学基金 (No .39970 874)资助项目
关键词 喜树碱 抗肿瘤药物 作用模式 柔性分子对接 拓扑异构酶 药物设计 camptothecin DNA topoisomerase molecular docking antineoplastic drug mode of action drug design
  • 相关文献

参考文献29

  • 1宋云龙,张万年,季海涛,周有骏,朱驹,吕加国.喜树碱构象的量子化学研究及其与晶体结构的比较[J].中国药物化学杂志,2001,11(4):187-192. 被引量:9
  • 2宋云龙,张万年,季海涛,盛春泉,周有骏,朱驹,吕加国.喜树碱类抗肿瘤药物的量子化学与定量构效关系研究[J].计算机与应用化学,2002,19(1):4-8. 被引量:19
  • 3Wang, J C Annu, Rev, Biochem 1996, 65, 635.
  • 4Takimoto, C H; Wright, J; Arbuek, S G Biochim Biophys Acta 1998, 1400, 107.
  • 5Iyer, L ; Ratain, M J Cancer Chemother Pharmacol 1998,42(Suppl ), S31.
  • 6Pommier, Y; Pourquier, P; Fan, Y; Strumberg,D Biochim Biophys Acta 1996, 1400, 83.
  • 7Fan, Y; Weinstein, J N; Kohn, K W; Shi, L M;Pommier, Y J Med Chem 1996, 41, 2216.
  • 8Redinbo, M R; Stewart, L; Kuhn, P; Champoux, J J;Hol, W G Science 1996, 279, 1504.
  • 9Kerrigan, J E ; Pilch, D S Biochemistry 2001, 40, 9792.
  • 10Laco, G S ; Collins, J R ; Lake, B T ; Kroth, H ; Sayer,J M ; Jerina, D M ; Pommier, Y Biochemistry 2002, 41,1428.

二级参考文献19

  • 1Wang X Y,Biochemistry,1999年,38卷,14期,4374页
  • 2朱杰,中国药学杂志,1999年,9卷,4期,694页
  • 3Fan Y,J Med Chem,1998年,41卷,13期,2216页
  • 4Redinbo M R,Science,1998年,279卷,5356期,1504页
  • 5Carrigan S W,J Comput Aided Mol Des,1997年,11卷,1期,71页
  • 6Hsiang Y H,Cancer Res,1988年,48卷,7期,1722页
  • 7朱杰,中国药物化学杂志,9卷,4期,277页
  • 8Hsiang Y H,Liu L F.Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.Cancer Res,1988,48(7):1722-1726.
  • 9Fan Y,Weinstein J N,Kohn K W,et al.Molecular modeling studies of the DNA-topoisomerase iternary cleavable complex with camptothecin.J Med Chem,1998,41(13):2216-2226.
  • 10Redinbo M R,Stewart L,Kuhn P,et al.Crystal structures of human topoisomerase I in covalentand noncovalent complexes with DNA.Science ,1998,279(5356):1504-1513.

共引文献24

同被引文献113

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部